Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | GAPDH | P04406 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644745 | 1.00 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL18511052 | 1.00 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL29471806 | 1.00 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL18822706 | 0.96 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL24499270 | 0.94 | TYMP (0.39) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL29581997 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL26535891 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL24878603 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL668595 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL25873876 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3868384-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-25 | — | — | EP | disclosed |
| EP-3694867-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-26 | — | — | US | disclosed |
| US-12171777-B2 | Methods of making a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-12-24 | — | — | US | disclosed |
| EP-3697801-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11667663-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| EP-3676278-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-12 | — | — | EP | disclosed |
| US-9994607-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| US-9994607-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| US-20180064745-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20170233430-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2017-08-17 | — | — | US | disclosed |
| US-20170233430-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2017-08-17 | — | — | US | disclosed |
| US-9718848-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| US-9718848-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| US-20170158724-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158724-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| WO-2017093933-A1 | CYCLIC PURINE DINUCLEOTIDES AS MODULATORS OF STING | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | TYMP 408/4885PRMT6 1082/4885PRKAG1 291/4885 |
| US-12171777-B2 | Methods of making a cyclic dinucleotide | STING1, CGAS, MAVS | TYMP 289/4885PRMT6 1713/4885PRKAG1 60/4885 |
| US-20170233430-A1 | Novel Compounds | STING1, IRF3, IFNAR1 | TYMP 1531/4885PRMT6 2225/4885PRKAG1 1804/4885 |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | STING1, CGAS, TLR9 | TYMP 365/4885PRMT6 1404/4885PRKAG1 412/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | TYMP 408/4885PRMT6 1082/4885PRKAG1 291/4885 |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | TYMP 5/4885PRMT6 1652/4885PRKAG1 503/4885 |
| US-11667663-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, DUT | TYMP 5/4885PRMT6 1311/4885PRKAG1 464/4885 |
| US-20170158724-A1 | Novel Compounds | STING1, IRF3, IFNAR1 | TYMP 1531/4885PRMT6 2225/4885PRKAG1 1804/4885 |
| US-20180064745-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | STING1, IRF3, CGAS | TYMP 1369/4885PRMT6 4082/4885PRKAG1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.